By Mark Zipkin, Staff Writer
The Innovative Medicines Initiative (IMI) is broadening its base in its latest call for proposals by bringing in funding partners from the non-profit sector. The new partners will add to the portfolio of projects backed through the EU's Horizon 2020 framework and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Under the second phase of IMI, "associate partner" non-profits are a core component of the strategy to expand the slate of stakeholders. Catherine Brett, external relations manager for IMI, told BioCentury that although non-profits were able to contribute funds under IMI 1, "that kind of contribution wasn't recognized in a formal way." Under IMI 2 they can now compete on an equal footing with the private sector for matching funds.